Sun to stop US oxaliplatin sales this month pending appeal
This article was originally published in Scrip
Executive Summary
Sun Pharma will stop selling its generic version of Sanofi-Aventis's anticancer Eloxatin (oxaliplatin injection) in the US at the end of June, after a US court denied Sun's motion seeking a suspension of a previous order.